Ganciclovir Susceptibilities of Cytomegalovirus (CMV) Isolates from Solid Organ Transplant Recipients with CMV Viremia after Antiviral Prophylaxis

• Published in: The Journal of infectious diseases Vol. 168; no. 2; pp. 332 - 335
• Main Authors: Boivin, Guy, Erice, Alejo, Crane, Deborah D., Dunn, David L., Balfour, Henry H.
• Format: Journal Article
• Language: English
• Published: Chicago, IL The University of Chicago Press 01.08.1993; University of Chicago Press
• Subjects: Acyclovir - therapeutic use; Analysis of Variance; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiviral agents; Antiviral Agents - pharmacology; Antivirals; Biological and medical sciences; Blood; Bone marrow diseases; Cytomegalovirus; Cytomegalovirus - drug effects; Cytomegalovirus - physiology; Cytomegalovirus infections; Cytomegalovirus Infections - microbiology; Cytomegalovirus Infections - prevention & control; Drug Resistance, Microbial; Ganciclovir - pharmacology; Ganciclovir - therapeutic use; Humans; Infections; Medical sciences; Organ Transplantation; Pharmacology. Drug treatments; Preventive medicine; Prospective Studies; Transplantation; Viremia; Viremia - microbiology; Viremia - prevention & control; Viruses; Human; Cytomegalovirus; Viremia; Herpesviridae; Homotransplantation; Betaherpesvirinae; In vitro; Infection; Virus; Prevention; Chemotherapy; Sensitivity resistance; Treatment; Viral disease; Minimum inhibitory concentration; Antiviral; Organ
• ISSN: 0022-1899; 1537-6613
• DOI: 10.1093/infdis/168.2.332

Ganciclovir susceptibility studies were done on the last cytomegalovirus (CMV) isolate available from 42 solid organ transplant recipients with CMV viremia who were enrolled in a prospective CMV prophylactic trial. Viruses were categorized as follows: 13 isolates (group 1) from patients who received ganciclovir prophylaxis; 9 isolates (group 2) from patients who received acyclovir prophylaxis; 8 isolates (group 3) from patients who received acyclovir prophylaxis and ganciclovir treatment; and 12 isolates (group 4) from patients who received prophylaxis and treatment with ganciclovir. All CMV isolates were sensitive to ganciclovir (mean 50% inhibitory concentration [IC50] = 1.7 µM; range, 0.2-5.3 µM). Mean IC50 values (in µM) were 1.7 for group 1 isolates, 1.2 for group 2 isolates, 2.2 for group 3 isolates, and 1.7 for group 4 isolates (P> .05). Thus, acyclovir or ganciclovir prophylaxis in solid organ transplant patients did not select ganciclovir- resistant isolates of CMV.